Kim et al. [34] evaluated 386 South Korean diabetic patients with BC and reported a decreased risk of BC-specific death associated with post-diagnostic use of metformin, compared to non-metformin antidiabetics, in patients with ER + and/or PR + BC but not in patients with BC with both ER- and PR-. This evidence concerns the gene PGR and breast cancer.